CD40, also known as TNFSF5, is a type I transmembrane protein and member of the TNF receptor family. The binding of CD40L (CD154) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 is expressed on B cells, dendritic cells, monocytes, thymic epithelial cells and, at low levels, on T cells. Signaling though CD40 plays an important role in the proliferation and differentiation of B cells and is critical for immunoglobulin (Ig) class switching. The membrane-anchored CD40L is expressed almost exclusively on activated CD4+ T lymphocytes. Failure to express CD40L leads to "immunodeficiency with hyper-IgM", a disease characterized by failure to produce IgG, IgA and IgE. Some of the early intracellular signaling by the CD4-CD40L system includes the association of the CD40 with TRAFs and the activation of various kinases (4). Adaptor protein TNFR2 interacts with this receptor and serves as a mediator of the signal transduction. The interaction of CD4-CD40L is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis.
| Catalog | IV0116 |
| Product Name | InVivoPro Anti-Mouse CD40 in vivo antibody, Clone FGK45 |
| Size | 1mg/5mg/25mg/50mg/100mg |
| Isotype | Rat IgG2a |
| Clone | FGK45 |
| Target | CD40 |
| Other Names | CD40, Bp50, TNFRSF5 |
| Isotype Control Catalog Code | IV0105 or Rat IgG2a Isotype Control |
| Dilution Buffer | PBS, pH 7.2, contains no stabilizers or preservatives |
| Reactivity | Mouse |
| Host Species | Rat |
| How much antibody to use in vivo | 200-500 μg per mouse; or 10-20 mg/kg. This range is based off the most recent publication data using the FGK45 clone in vivo. Each investigator should determine their own optimal working dilution for specific applications. |
| Background(ichorbio) | CD40, also known as TNFSF5, is a type I transmembrane protein and member of the TNF receptor family. The binding of CD40L (CD154) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 is expressed on B cells, dendritic cells, monocytes, thymic epithelial cells and, at low levels, on T cells. Signaling though CD40 plays an important role in the proliferation and differentiation of B cells and is critical for immunoglobulin (Ig) class switching. The membrane-anchored CD40L is expressed almost exclusively on activated CD4+ T lymphocytes. Failure to express CD40L leads to "immunodeficiency with hyper-IgM", a disease characterized by failure to produce IgG, IgA and IgE. Some of the early intracellular signaling by the CD4-CD40L system includes the association of the CD40 with TRAFs and the activation of various kinases (4). Adaptor protein TNFR2 interacts with this receptor and serves as a mediator of the signal transduction. The interaction of CD4-CD40L is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. |
| Applications | In vivo CD40 activation, in vitro B cell stimulation/activation, Flow cytometry |
| Purification | protein A or G |
| Storage | This antibody is stable for at least 2 months when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C or -80°C. Avoid repeated freeze thaw cycles. |
| Shipping | 2-8°C with blue ice |
| Concentration | Lot specific, generally ≥ 5.0 mg/ml |
| Shelf Life | 12 months from the date of receipt if stored as recommended |
| Formulation | PBS Buffer, PH 7.2, with no carrier protein, or preservatives. |
| Sterility | 0.2 μM filtered |
| Endotoxin | ≤ 1.0 EU/mg, by the LAL method |
| Purity | 99% |
Spitzer, Matthew H. et al. "Systemic Immunity is Required for Effective Cancer Immunotherapy",Cell 168.3 (2017): 487-502.e15.
Zhang, Lei et al. "Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer",Cell 181.2 (2020): 442-459.e29.
Wu, Renee et al. "Mechanisms of CD40-dependent Cdc1 Licensing Beyond Costimulation",Nature Immunology 208.1_Supplement (2022): 61.18-61.18.
© 2021-2025 InvivoCrown Limited. All rights reserved.